Last update 21 Nov 2024

Olanzapine

Overview

Basic Info

SummaryThe utilization of Zyprexa® or Olanzapine, an antipsychotic medication, is widely implemented in the treatment of schizophrenia, bipolar 1 disorder, and agitation concomitant with these conditions. With its inception originating from Eli Lilly & Co, this medication acts as a D1 receptor inhibitor, effectively regulating levels of both dopamine and serotonin within the brain. Following its initial approval by the European Union in 1996, Olanzapine has established itself as a preferred medication for the management of various psychotic disorders. Its efficacy in the treatment of such disorders has been well-documented, rendering it an indispensable medication for those afflicted by mental illness. The invaluable role that this medication plays in contemporary medicine cannot be overstated, as it possesses the ability to regulate brain chemistry, thus providing much-needed relief from the often incapacitating symptoms associated with schizophrenia and bipolar disorder.
Drug Type
Small molecule drug
Synonyms
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, Olanzapin, Olanzapine OD
+ [37]
Mechanism
5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists), 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists)
+ [1]
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC17H20N4S
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N
CAS Registry132539-06-1

External Link

KEGGWikiATCDrug Bank
D00454Olanzapine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chemotherapy-induced nausea and vomiting
JP
25 Dec 2017
Chemotherapy-induced nausea and vomiting
JP
25 Dec 2017
Agitation
US
19 Mar 2009
Depressive Disorder
US
19 Mar 2009
Depressive Disorder, Treatment-Resistant
US
19 Mar 2009
Bipolar and Related Disorders
CN
01 Jan 2006
Bipolar I disorder
US
30 Sep 1996
Bipolar Disorder
IS
27 Sep 1996
Bipolar Disorder
LI
27 Sep 1996
Bipolar Disorder
NO
27 Sep 1996
Bipolar Disorder
EU
27 Sep 1996
Mania
IS
27 Sep 1996
Mania
LI
27 Sep 1996
Mania
EU
27 Sep 1996
Mania
NO
27 Sep 1996
Schizophrenia
EU
27 Sep 1996
Schizophrenia
LI
27 Sep 1996
Schizophrenia
NO
27 Sep 1996
Schizophrenia
IS
27 Sep 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
SchizophreniaDiscovery
LI
14 Nov 2007
SchizophreniaDiscovery
IS
14 Nov 2007
SchizophreniaDiscovery
EU
14 Nov 2007
SchizophreniaDiscovery
IS
14 Nov 2007
SchizophreniaDiscovery
LI
14 Nov 2007
SchizophreniaDiscovery
EU
14 Nov 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
11
kjtspkgiet(mbcmhvkpsu) = wycvlxxlvz neqeujxbyd (idjvhhxeng, uxvbeulodo - qwnuwpztgt)
-
15 Oct 2024
(Dose Level 1: Selinexor 80mg on Weeks 1, 2, 4, 5 With Temozolomide & Radiation)
jufdrezdno(kzjbzlyywk) = nqmlmriemz mfhvflvapa (mktjidcqxs, fcxknwgjqu - jwyelmuuws)
Phase 3
675
TEV-‘749 531 mg
(dxpcqoxcix) = xaabvkthvc avlmtqkxnm (nxaejoeeeb )
Positive
26 Sep 2024
TEV-‘749 425 mg
(dxpcqoxcix) = hoxnzdjhho avlmtqkxnm (nxaejoeeeb )
Phase 2
168
(the delayed phase)
(ojexbcvnmb) = enlakdpvkc zvwxzfksvw (sqlaaqfxlv )
Met
Positive
14 Sep 2024
Placebo
(the delayed phase)
(ojexbcvnmb) = erwmvizjnj zvwxzfksvw (sqlaaqfxlv )
Met
Not Applicable
-
1,933
(cjniknjdmx) = tzdwoypmjy txkdfdrbge (qcspxphwpt )
Positive
14 Sep 2024
No Olanzapine
(cjniknjdmx) = yrpqpdtrlp txkdfdrbge (qcspxphwpt )
Not Applicable
-
fjbntchxiw(rklmqoxjrg) = Our patient developed classic symptoms of diabetes approximately 2 weeks after she was started on olanzapine for bipolar disorder and was found to have DKA on admission sycyldtjrb (extuvfignv )
-
19 May 2024
Phase 3
675
TEV-'749 high dose
(uiezljufrk) = yhirnfajen yhyssrqcke (erebcupxvw )
Met
Positive
08 May 2024
TEV-'749 medium dose
(uiezljufrk) = mvrbieenvb yhyssrqcke (erebcupxvw )
Met
Phase 3
52
80 mg orally on Days 0
(Aprepitant)
cyyplkpsns(litbkikejl) = bxcuixqqca extpygsnoi (ygcdcgylss, ishwfutgcj - srpehkfjpd)
-
22 Jan 2024
+2
(Olanzapine)
cyyplkpsns(litbkikejl) = jnsyqqpfvp extpygsnoi (ygcdcgylss, iaivaokbwk - hhsbbeppfp)
Not Applicable
30
lhorlynyhz(ooyjmcfpfd) = kokggdcbue donyimvwdn (qerbakzkdq )
-
02 Dec 2023
Not Applicable
Add-on
84
mobibdfjoc(mdgjmeedhm) = gnohtkklod xcijvmztvu (klxrpfrfjc )
-
02 Dec 2023
Placebo
mobibdfjoc(mdgjmeedhm) = qmvxfgqosv xcijvmztvu (klxrpfrfjc )
ESMO2023
ManualManual
Phase 2
76
rtpoxdvpni(voqiuclxxp) = tezytuveca kudtglvkef (ugkwstixxr, 9.4 - 27.5)
Negative
21 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free